561 related articles for article (PubMed ID: 28545354)
1. Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate.
Yasir M; Gaur PK; Puri D; Shehkar P; Kumar SS
Curr Drug Deliv; 2018; 15(6):818-828. PubMed ID: 28545354
[TBL] [Abstract][Full Text] [Related]
2. Quality by Design Approach for Development and Characterisation of Solid Lipid Nanoparticles of Quetiapine Fumarate.
Agarwal S; Murthy RSR; Harikumar SL; Garg R
Curr Comput Aided Drug Des; 2020; 16(1):73-91. PubMed ID: 31429691
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration.
Shah B; Khunt D; Misra M; Padh H
Eur J Pharm Sci; 2016 Aug; 91():196-207. PubMed ID: 27174656
[TBL] [Abstract][Full Text] [Related]
4. Quetiapine Fumarate Loaded Nanostructured Lipid Carrier for Enhancing Oral Bioavailability: Design, Development and Pharmacokinetic Assessment.
Agarwal S; HariKumar SL; Negi P; Upadhyay N; Garg R
Curr Drug Deliv; 2021; 18(2):184-198. PubMed ID: 32723273
[TBL] [Abstract][Full Text] [Related]
5. "Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* ".
Shah B; Khunt D; Misra M; Padh H
Int J Biol Macromol; 2016 Aug; 89():206-18. PubMed ID: 27130654
[TBL] [Abstract][Full Text] [Related]
6. Preparation, Characterization and Evaluation of Quetiapine Fumarate Solid Lipid Nanoparticles to Improve the Oral Bioavailability.
Narala A; Veerabrahma K
J Pharm (Cairo); 2013; 2013():265741. PubMed ID: 26555970
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
8. Bio-shielding In Situ Forming Gels (BSIFG) Loaded With Lipospheres for Depot Injection of Quetiapine Fumarate: In Vitro and In Vivo Evaluation.
Abo Elela MM; ElKasabgy NA; Basalious EB
AAPS PharmSciTech; 2017 Nov; 18(8):2999-3010. PubMed ID: 28493003
[TBL] [Abstract][Full Text] [Related]
9. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement.
Sanjula B; Shah FM; Javed A; Alka A
J Drug Target; 2009 Apr; 17(3):249-56. PubMed ID: 19255893
[TBL] [Abstract][Full Text] [Related]
10. Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate.
Gonçalves de Lima L; Rossi de Campos D
Drug Res (Stuttg); 2016 May; 66(5):225-9. PubMed ID: 26697891
[TBL] [Abstract][Full Text] [Related]
11. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement.
Mandpe L; Pokharkar V
Pharm Dev Technol; 2015 May; 20(3):320-9. PubMed ID: 24328553
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of In Vivo Efficacy and Oral Bioavailability of Aripiprazole with Solid Lipid Nanoparticles.
Silki ; Sinha VR
AAPS PharmSciTech; 2018 Apr; 19(3):1264-1273. PubMed ID: 29313261
[TBL] [Abstract][Full Text] [Related]
13. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
[TBL] [Abstract][Full Text] [Related]
14. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization,
Patel MH; Mundada VP; Sawant KK
Drug Dev Ind Pharm; 2019 Aug; 45(8):1242-1257. PubMed ID: 30880488
[No Abstract] [Full Text] [Related]
15. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
16. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
17. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics.
Fatouh AM; Elshafeey AH; Abdelbary A
Drug Des Devel Ther; 2017; 11():1815-1825. PubMed ID: 28684900
[TBL] [Abstract][Full Text] [Related]
18. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
19. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
Pandya NT; Jani P; Vanza J; Tandel H
Colloids Surf B Biointerfaces; 2018 May; 165():37-44. PubMed ID: 29453084
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration.
Manjunath K; Venkateswarlu V
J Control Release; 2005 Oct; 107(2):215-28. PubMed ID: 16014318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
